Status:
TERMINATED
The Effect of a Probiotic on Hepatic Steatosis
Lead Sponsor:
VSL Pharmaceuticals
Conditions:
Fatty Liver
Eligibility:
All Genders
45-70 years
Phase:
PHASE1
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States. The exact cause of NAFLD...
Eligibility Criteria
Inclusion
- Adult-onset diabetes
- Liver biopsy in the previous 2 months with diagnosis of fatty liver and fibrosis stage F2-F3
Exclusion
- There are multiple exclusion criteria.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00099723
Start Date
October 1 2004
End Date
December 1 2005
Last Update
February 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287